Pharminox appoints Scientific Advisory Board
Nottingham, UK, 17 February 2009 - Pharminox Limited, ("Pharminox" or "the Company") the UK-based cancer drug discovery and development company, today announced that it has completed the appointment of its Scientific Advisory Board to provide independent expert advice and guidance on the Company’s research and development portfolio. The inaugural members of the Pharminox Scientific Advisory Board will be Dr Lee Arnold, Professor Adrian Harris and Dr Robert Jackson.
Dr Arnold was formerly Vice President of US Research for OSI Pharmaceuticals, and is the inventor of erlotinib (marketed as Tarceva® for non-small cell lung cancer and pancreatic cancer by Roche/Genentech/OSI). Professor Harris is the Cancer Research UK Professor of Medical Oncology at the University of Oxford and is an internationally renowned medical oncologist; Dr Jackson has held numerous senior R&D positions with biotechnology and pharma companies in a long and distinguished career, and has been involved in a senior capacity in bringing 25 NCEs into clinical trials, five of which ultimately received marketing approval.
Commenting on today’s announcement, Peter Worrall, Chief Executive of Pharminox said, “The appointment of our first Scientific Advisory Board marks another important step in the evolution of Pharminox as a growing force in UK cancer drug discovery and development. It is testimony to the quality of the Pharminox programmes that we have been able to attract three individuals of the calibre and reputation of Dr Arnold, Professor Harris and Dr Jackson. Between them they bring an exceptional breadth of expertise and experience. I am delighted to welcome all of them to Pharminox and I very much look forward to working with them.”